PERFORMANCE / SINGLE
CJC-1295 NO DAC
5MG · 10MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
Modified GRF(1-29) without the DAC extension, studied in growth-hormone pulsatility research.
Available Strengths
- 5MG (CND5)
- 10MG (CND10)
Research Protocol
Reference gradual titration
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–2 | 0.1 mg | 6 | 0.06 mL |
| Weeks 3–4 | 0.15 mg | 9 | 0.09 mL |
| Weeks 5–6 | 0.2 mg | 12 | 0.12 mL |
| Weeks 7–12 | 0.25 mg | 15 | 0.15 mL |
Reconstitution
≈1.67 mg/mL once reconstituted
- Draw 3.0 mL of bacteriostatic water per 5 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Reported to bind GHRH receptors on pituitary cells, triggering pulsatile endogenous growth-hormone secretion while preserving physiologic feedback regulation; its short half-life (versus the DAC form) supports once-daily dosing in the reference protocol.
Storage
2–8°C refrigerated, or ≤−20°C frozen for extended storage. 2–8°C, use within 1–2 weeks; avoid freeze–thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source